At present, the studies on the role of CD36 in the occurrence and development of eye diseases mainly focus on AMD, DR, etc., and it has been found that TSP-1, EP80317, MPE-001, and other proteins or derivative ligands can interact with CD36 to inhibit the pathological processes such as abnormal lipid metabolism, oxidative stress damage, or vascular abnormalities through intracellular signal transduction. This evidence concerns the gene CD36 and age-related macular degeneration.